Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR -Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments - Archive ouverte HAL Access content directly
Journal Articles Cancer Management and Research Year : 2020

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR -Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments

(1) , (2)
1
2

Abstract

Non-small cell lung cancer (NSCLC) is one of the most efficient models for precision medicine in oncology. The most appropriate therapeutic for the patient is chosen according to the molecular characteristics of the tumor, schematically distributed between immunogenicity and oncogenic addiction. For this last concept, advanced NSCLC with epidermal growth factor receptor (EGFR) mutation is one of the most illustrative models. EGFR-tyrosine kinase inhibitors (TKIs) are the therapeutic backbone for this type of tumor. The recent development of a third-generation TKI, osimertinib, has been a new step forward in the treatment of NSCLC patients. In this article, we first review the clinical development of osimertinib and highlight its efficacy results. We then present the most frequent tumor escape mechanisms when osimertinib is prescribed in first line: off-target (MET amplification, HER2 amplification, BRAF mutation, gene fusions, histologic transformation) and on-target mechanisms (EGFR mutation). Finally, we discuss subsequent biomarker-driven treatment strategies.

Dates and versions

inserm-03498514 , version 1 (21-12-2021)

Identifiers

Cite

Marc Denis, Jaafar Bennouna. Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR -Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments. Cancer Management and Research, 2020, Volume 12, pp.12593-12602. ⟨10.2147/CMAR.S218751⟩. ⟨inserm-03498514⟩
10 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More